Why Did Compass Pathways Stock Rocket Higher Today?
Key Points
Phase 3 clinical trial data has been a success.
COMP360 is the first traditional psychedelic to consistently deliver a highly statistically significant outcome.
Results included maintaining a generally well-tolerated and safe profile.
- 10 stocks we like better than Compass Pathways Plc ›
It's been a long road for Compass Pathways (NASDAQ: CMPS) to prove that its treatment using psilocybin therapy for treatment-resistant depression (TRD) can be successful. It was back in 2018 when the company received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for its treatment.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Today, Compass updated investors on its drug trial progress, and the stock shot higher. Compass announced two Phase 3 trials that were statistically significant and positive, with plans to formally submit a New Drug Application (NDA) to the FDA for approval.
Shares initially rocketed more than 50% higher on the news. As of 11:30 a.m. ET, Compass stock was trading up by 42.3%
Image source: Getty Images.
Primary endpoint achieved
The second of two Phase 3 trials successfully met its primary endpoint in evaluating two fixed doses of COMP360. That's the company's proprietary formulation of psilocybin for TRD.
CEO Kabir Nath released the following statement:
Across three robust, well-designed and well-executed clinical trials involving more than 1,000 participants, we have now demonstrated consistent, highly statistically significant results at the primary endpoint and a clinically meaningful effect. This is a remarkable achievement for the field of psychiatry-especially in the TRD population, where proving benefit has historically been extraordinarily challenging.
There are currently limited treatment options for TRD patients. Compass has now requested a meeting with the FDA and plans to submit an NDA seeking full approval before the end of this year.
That has investors jumping into this biotech stock today. Today's news is a meaningful step in the lengthy trial and approval process. The next step will be to hear from the FDA, and a positive response could keep the stock soaring.
Should you buy stock in Compass Pathways Plc right now?
Before you buy stock in Compass Pathways Plc, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Compass Pathways Plc wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $414,554!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,120,663!*
Now, it’s worth noting Stock Advisor’s total average return is 884% — a market-crushing outperformance compared to 193% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 17, 2026.
Howard Smith has positions in Compass Pathways Plc. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
